Swiss Roche ups sales in Russia 2% in 2013
MOSCOW. Jan 30 (Interfax) - Swiss pharmaceuticals company Roche Holding AG increased sales in Russia 2.4% in 2013 to 653 million Swiss francs ($725.96 million), the company reported.
Sales by Roche Pharmaceuticals grew 1.1% to 444 million francs ($493.6 million) and sales by Roche Diagnostics climbed 5% to 209 million francs ($232.35 million).
Roche group sales overall reached 46.78 billion francs ($52 billion) in 2013, up 2.8% on 2012. Sales of pharmaceuticals rose by 3% to 36.3 billion francs ($40.36 billion) and diagnostics system sales increased by 2% to 10.48 billion francs ($11.65 billion).
Roche posted net profit of 11.37 billion francs ($12.7 billion), jumping 17.7%.
Roche manufactures biotechnological pharmaceuticals to treat cancer, serious viral infections, autoimmune inflammatory diseases, disorders of the central nervous system and metabolic disorders.
In Russia, the company is implementing a project to localize production of MabThera, a rheumatoid arthritis treatment, at OJSC Pharmstandard-UfaVITA in Ufa, which is part of Pharmstandard . Roche plans to launch full-cycle production of the treatment at the Ufa plant in 18 months to two years.
